

21 February 2014

Kimberley Brown
Senior Adviser, Listings Compliance (Sydney)
ASX Compliance Pty Ltd
20 Bridge Street
Sydney NSW 2000

Reply to ASX price query

Dear Kimberley

I refer to your letter dated 20 February 2014 which noted a change in the price of Benitec Biopharma Limited (the 'Company') securities as well as an increase in the volume of trading since Wednesday 19 February 2014.

The responses to your questions are:

1. The Company is not aware of any information concerning it that has not been announced to the market, which, if known by someone in the market, could explain recent trading in its securities.
2. Not applicable.
3. Following receipt of approval in January 2014 by the US-FDA to proceed with clinical trials for TT-034 in infected hepatitis C patients, Benitec provided an update in an announcement on 18 February 2014 regarding the likely timeframe for dosing of the first patient. The Company considers that this announcement may have had an impact on the Company's share price and trading. Another potential explanation relates to increased interest in the sector. Benitec specialises in the field of RNAi therapeutics with its proprietary DNA directed RNA interface (ddRNAi) platform technology. The Company has observed announcements made and stock movements in the past 48 hours by other companies operating in the broader field of RNAi therapeutics. These activities suggest increased investor interest in companies active in the field of RNAi therapeutics.
4. The Company is in compliance with the Listing Rules and, in particular, Listing Rule 3.1.

Yours faithfully



Greg West
Secretary



ASX Compliance Pty Limited
ABN 26 087 780 489
20 Bridge Street
Sydney NSW 2000
PO Box H224
Australia Square
NSW 1215

20 February 2014

Mr Greg West
Company Secretary
Benitec Biopharma Limited
Level 16, 356 Collins Street
Melbourne VIC 3000

Telephone 61 2 9227 0000
Facsimile 61 2 9241 7620
www.asx.com.au

Dear Mr West,

Benitec Biopharma Limited (the "Company"): ASX price query

We have noted a change in the price of the Company's securities from a close of \$0.99 on Wednesday, 19 February 2014 to a close of \$1.26 today, Thursday 20 February 2014. We have also noted an increase in the volume of trading in the Company's securities over this period.

In light of the price change and increase in volume, ASX asks you to respond separately to each of the following questions.

1. Is the Company aware of any information concerning it that has not been announced to the market which, if known by some in the market, could explain the recent trading in its securities?
2. If the answer to question 1 is "yes":
 - a) Is the Company relying on Listing Rule 3.1A not to announce that information under Listing Rule 3.1?

Please note that the recent trading in the Company's securities would suggest to ASX that such information may have ceased to be confidential and therefore the Company may no longer be able to rely on Listing Rule 3.1A. Accordingly, if the answer to this question is "yes", you need to contact us immediately to discuss the situation.
 - b) Can an announcement be made immediately?

Please note, if the answer to this question is "no", you need to contact us immediately to discuss requesting a trading halt (see below).
 - c) If an announcement cannot be made immediately, why not and when is it expected that an announcement will be made?
3. If the answer to question 1 is "no", is there any other explanation that the Company may have for the recent trading in its securities?
4. Please confirm that the Company is in compliance with the Listing Rules and, in particular, Listing Rule 3.1.

When and where to send your response

This request is made under, and in accordance with, Listing Rule 18.7. Your response is required as soon as reasonably possible and, in any event, by no later than 9:30 a.m. AEDT on Friday, 21 February 2014. If we do not have your response by then, ASX will have no choice but to consider suspending trading in the Company's securities under Listing Rule 17.3.

You should note that if the information requested by this letter is information required to be given to ASX under Listing Rule 3.1 and it does not fall within the exceptions mentioned in Listing Rule 3.1A, the Company's obligation is to disclose the information "immediately". This may require the information to be disclosed before the deadline set out in the previous paragraph.

ASX reserves the right to release a copy of this letter and your response on the ASX Market Announcements Platform under Listing Rule 18.7A. Accordingly, your response should be in a form suitable for release to the market.

Your response should be sent to me by e-mail or by facsimile to (02) 9241 7620. It should not be sent directly to the ASX Market Announcements Office. This is to allow me to review your response to confirm that it is in a form appropriate for release to the market, before it is published on the ASX Market Announcements Platform.

Listing Rule 3.1

Listing Rule 3.1 requires a listed entity to give ASX immediately any information concerning it that a reasonable person would expect to have a material effect on the price or value of the entity's securities. Exceptions to this requirement are set out in Listing Rule 3.1A.

The obligation of the Company to disclose information under Listing Rules 3.1 and 3.1A is not confined to, nor is it necessarily satisfied by, answering the questions set out in this letter.

In responding to this letter, you should have regard to the Company's obligations under Listing Rules 3.1 and 3.1A and also to Guidance Note 8 *Continuous Disclosure: Listing Rules 3.1 – 3.1B*.

Trading halt

If you are unable to respond to this letter by the time specified above, or if the answer to question 1 is "yes" and an announcement cannot be made immediately, you should discuss with us whether it is appropriate to request a trading halt in the Company's securities under Listing Rule 17.1.

If you wish to request a trading halt, you must tell us:

- the reasons for the trading halt;
- how long you want the trading halt to last;
- the event you expect to happen that will end the trading halt;
- that you are not aware of any reason why the trading halt should not be granted; and
- any other information necessary to inform the market about the trading halt, or that we ask for.

We may require the request for a trading halt to be in writing. The trading halt cannot extend past the commencement of normal trading on the second day after the day on which it is granted.

You can find further information about trading halts in Guidance Note 16 *Trading Halts & Voluntary Suspensions*.

If you have any queries or concerns about any of the above, please contact me immediately.

Yours sincerely,

[Sent electronically without signature]

Kimberley Brown
Senior Adviser, Listings Compliance (Sydney)